



Contact
Raymond Woosley, MD, PhD
Critical Path Institute
(520) 547-3440

For Immediate Release
January 8, 2008

Dr. Peter B. Corr Joins Critical Path Institute Board of Directors

The Critical Path Institute today announced that Peter B. Corr, Ph.D., has joined its Board of Directors. Dr. Corr has more than 30 years of pharmacology and pharmaceutical development experience as both an academician and a senior executive in the pharmaceutical industry. He is currently Founder and General Partner, Celtic Therapeutics, L.L.P., a private equity firm focused on acquiring projects in mid-stage clinical development, and developing these further to approval for subsequent auction to the pharmaceutical industry.

Dr. Corr recently retired from Pfizer Inc, where he was Senior Vice President, Science and Technology, from 2002 to 2006, with responsibility for aligning Pfizer's worldwide research and development organization with licensing activities, science and medical advocacy, global medical relations and science policy. He previously headed Worldwide Research and Development at Pfizer, and prior to that served as Executive Vice President, Pfizer's Global Research and Development, and as President, Worldwide Development. Prior to joining Pfizer, he served as President of Pharmaceutical Research and Development at Warner Lambert/Parke Davis until the merger with Pfizer in 2000. Dr. Corr served previously as Senior Vice President, Discovery Research, at Monsanto/Searle. He came to the private sector after spending 18 years as a researcher in molecular biology and pharmacology at Washington University in St. Louis, where he was a professor in the Departments of Medicine (Cardiology) and Pharmacology and Molecular Biology. Dr. Corr also serves on a number of for-profit and not-for-profit boards and councils. His research is published in more than 160 scientific manuscripts.

President and CEO, Dr. Raymond Woosley, said that the Critical Path Institute is extremely pleased to have Dr. Corr as a member of the Board of Directors because of his “outstanding scientific and real world experience” in the area of global health. “Dr. Corr has invaluable expertise working on the challenges of drug development around the world.” Dr. Janet Woodcock, Deputy Commissioner of the Food and Drug Administration and FDA liaison member of the Board said, “It will be great working with Dr. Corr in this capacity. He will add an extremely valuable perspective to the Board.”

About the Critical Path Institute

Headquartered in Tucson, Arizona with offices in Rockville, Maryland, the Critical Path Institute was established in 2005 as a publicly funded, nonprofit research and education institute to enable collaborations between scientists from the FDA, industry and academia. The Critical Path Institute’s mission is to help implement the FDA’s Critical Path Initiative by developing faster, safer and smarter pathways to new medical products. Visit www.C-Path.org for more information.